As reported recently in the New York Times (Business Day, March 20, 2015, “Biogen Reports Its Alzheimer’s Drug Sharply Slows Cognitive Decline”) and other media, the pharmaceutical company Biogen has announced impressive results in a Phase I “human safety” trial of a new drug designed to treat — and possibly prevent — Alzheimer’s disease.
Find updates on the work of our researchers here, as well as news about recent advances in Alzheimer's science, funding and awareness.
- Page 1
© 2005-2015 Cure Alzheimer's Fund. All rights reserved.